ctDNA for Predicting Immunotherapy in Colorectal Cancer
Circulating Tumor DNA (ctDNA) as a Predictive Biomarker for Immunotherapy in Advanced or Locally Advanced dMMR/MSI-H Colorectal Patients
Recruiting
Observational Study
Colorectal Cancer
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 80
- Sex
- Any
- Study type
- Observational
- Participants needed
- 60 (estimated)
- Sponsor
- Geneplus-Beijing Co. Ltd. · Industry
Who this trial is looking for
This trial is looking for people with advanced or locally advanced colorectal cancer who may receive a specific immune therapy. Participants will help researchers understand how ctDNA can predict treatment effectiveness.
Are You a Good Fit for This Trial?
You may be able to join if
- I have been diagnosed with advanced or locally advanced dMMR/MSI-H colorectal cancer
- I expect to receive immune checkpoint inhibitor therapy
- My ECOG performance score is 0-1
- I have a life expectancy of at least 12 weeks
You may not be able to join if
- I have other uncured cancers
- I have serious systemic diseases that affect my ability to complete the study
- I have an autoimmune disease
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
dMMR/MSI-H colorectal cancer patients are the dominant population of immunotherapy/neoadjuvant immunotherapy, but imaging evaluation of immunotherapy efficacy is insufficient. There are some cases, although no disease remission was found on imaging,pathological complete response (pCR) was confirmed after surgery. Meanwhile,previous studies have shown that dynamic changes in ctDNA can help assess i…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
\- advanced or locally advanced dMMR/MSI-H colorectal cancer Expected to receive/be receiving immune checkpoint inhibitor therapy ECOG performance score is 0-1, life expectancy ≥12 weeks
Exclusion Criteria:
\- The presence of other uncured malignancies Patients with one or mor…
Contacts